Company news

Neuren Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA approval for Angelman IND and Phase 2 trial

February 24, 2022

2021 Results - a transformational year for Neuren

February 23, 2022

Preliminary Final Report and 2021 Full Year Accounts

February 23, 2022

Notification regarding unquoted securities - NEU

February 3, 2022

Q4 2021 quarterly activity and cash flow report

January 30, 2022

Positive topline results from Phase 3 trial in Rett syndrome

December 6, 2021

Neuren presenting at Bell Potter Healthcare Conference

November 9, 2021

Q3 2021 quarterly activity and cash flow report

October 27, 2021

Neuren receives feedback on IND for Phelan-McDermid syndrome

October 21, 2021

US patent to 2034 granted for Neurens NNZ-2591 in autism

October 10, 2021

$3.3 million raised from oversubscribed SPP

October 5, 2021

Feedback on Angelman IND and submission of Pitt Hopkins IND

October 1, 2021

IND application submitted for NNZ-2591 in Phelan-McDermid

September 20, 2021

Share Purchase Plan Offer Booklet

September 16, 2021

New patent issued to 2032 for Neurens trofinetide in Brazil

September 16, 2021

Investor Presentation, 13 September 2021

September 12, 2021

Proposed issue of securities - NEU

September 12, 2021

Placement to accelerate NNZ-2591 across 4 indications

September 12, 2021

FDA grants Orphan Drug designation for Prader-Willi syndrome

September 3, 2021

Angelman IND and Ethics applications submitted for NNZ-2591

August 31, 2021

R&D Tax Incentive Advance Overseas Finding Approval

August 30, 2021

Phase 3 enrolment successfully completed, results in Q4 2021

August 4, 2021

Q2 2021 quarterly activity and cash flow report

July 30, 2021

Positive FDA meetings enable INDs for three Phase 2 trials

May 31, 2021

New patent issued to 2032 for Neurens trofinetide in Canada

April 28, 2021

Quarterly report and cash flow statement for Q1 2021

April 22, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Neuren successfully completes manufacturing for Phase 2

March 9, 2021

Neuren approaching transforming milestones in 2021

February 23, 2021

Preliminary Final Report and 2020 full year accounts

February 23, 2021

Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

February 15, 2021

Successful Phase 1 trial for Neurens NNZ-2591

February 14, 2021

Quarterly report and cash flow statement for Q4 2020

January 28, 2021

European Commission grants 3 NNZ-2591 Orphan designations

January 10, 2021

Positive opinion for all 3 Orphan applications in Europe

December 6, 2020

Approval received for final stage of NNZ-2591 clinical trial

November 18, 2020

Quarterly report and cash flow statement for Q3 2020

October 28, 2020

Neuren initiates manufacture of NNZ-2591 for Phase 2 trials

September 22, 2020

Q2 2020 Activity Report and Cash Flow Report

July 27, 2020

Proposed issue of Securities - NEU

June 28, 2020

Neuren successfully completes $20m capital raising

June 28, 2020

Temporary enrolment pause ended in Phase 3 trial in the US

June 15, 2020

Neuren announces changes to leadership team

May 26, 2020

Neuren commences first clinical trial for NNZ-2591

May 7, 2020

Appendix 4C - quarterly

April 17, 2020

Q1 2020 Activity Report

April 16, 2020

First patent in Israel granted for trofinetide

April 1, 2020

Temporary pause in new enrolments for LAVENDER trial in US

March 23, 2020

Neuren to capture substantially greater value after Phase 3

March 16, 2020

Compelling results for 2591 dose ranging study in PMS model

March 5, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 91 decks. Every deck is listed under its year.